 |
인쇄하기
취소
|
Green Cross reports positive results from phase 3 trials of Peramivir for influenza
Green Cross Corporation announced on July 28 the positive results from two Phase 3 studies of intravenous peramivir in patients with seasonal influenza.
The studies were sponsored by the US based BioCryst's partner Shionogi & Co., Ltd. of Osaka, Japan and conducted during the 2008-2009 influenza season. Shionogi and GCC, the license holder of peramivir in Korea, co-conducted the portion of t...
The studies were sponsored by the US based BioCryst's partner Shionogi & Co., Ltd. of Osaka, Japan and conducted during the 2008-2009 influenza season. Shionogi and GCC, the license holder of peramivir in Korea, co-conducted the portion of t...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.